Is the studyof this group of NHL, see a report of the MD Anderson Cancer Center go Gardens two recurring patients with rituximab with or without DLI treatment. Limonin The two achieved CR. The consortium also reported on the transplantation of Seattle, the result of two patients with relapsed follicular Ren NHL. Re-election U rituximab and DLI implemented and a second long-term CR, the other achieved with early post-transplant progression sustained CR long after discontinuation of immunosuppression. The risk of a relapse seems grafts depleted of T cells following, which are offset by T cells k Can or a scheduled DLI Porter et al. Page 19 of Biol Blood Marrow Transplant. Author manuscript, increases available in PMC 2011 November 1 .
. Morris et al. reactions reported in six PI-103 of 10 patients, the DLI for relapse after transplantation with a di t with reduced intensity t alemtuzumab, and Ingram et al CR in four of six patients, the DLI for relapse after an intensive regimen BEAM alemtuzumab. Thus, a reasonable strategy for patients with indolent NHL who relapsed or persistent disease in the absence of GVHD, the withdrawal of immunosuppression therapy with monoclonal antibodies Rpern and DLI to envisage. For patients who can not to this approach, or those with GVHD, the treatment include antique Body therapy, chemo-radiotherapy with the aim of achieving a CR and the restoration of the contr The GVT. Second allogeneic transplantation should be considered, but not yet fully investigated.
The treatment of relapsed aggressive NHL following alloHSCT aggressive NHL is often difficult due to the fast-VER Santander ligand nature of the disease. In addition, many patients are resistant to chemotherapy, and most of them failed regimen and autologous HSCT high dose before considered for alloHSCT. Comorbid disease status, sensitivity to chemotherapy, the disease burden and the patient are all important factors that increase the risk of relapse in most studies. Rezvani et al. Seattle transplant consortium report on six patients relapse after myeloablative therapy very lowdose not. Two of the six patients achieved CR after long-term or a second transplant or radiation, rituximab and narrowing of immunosuppression. DLI was ineffective in two others. A report by Thomson et al.
in patients receiving reduced intensity t conditioning with alemtuzumab, fludarabine and melphalan containing information about patients with recurrent primary Ren DLBCL fifth One was a long-term survivors after surgery, radiotherapy, rituximab and DLI. Sirvent et al. recently on the use of allogeneic transplantation in patients with aggressive DLBCL in the registry Fran Transplants reported. Twenty of 26 patients died with recurrent disease remain, five CR after treatment of relapse with various combinations of chemotherapy, radiotherapy and DLI. Treated transplant in a series of 44 patients in the Vancouver BC with myeloablative conditioning and 13 patients were alloHSCT progression or relapse, and then End all died of disease. The result of the DLI or withdrawal of immunosuppression in aggressive NHL was reported in 15 patients with signs of disease or relapse by day 100 after allotransplantation by Bishop et al .. Six of the eleven patients with immunosuppression or withdrawal of DLI alone Answers treated, and 3 of 4 patients treated with chemotherapy and DLI responded. Six patients remained in a com